Table 2.

Survival comparison

No. of patientsMedian survival (95% CI), moOverall survival at 6 mo, % (95% CI)Overall survival at 12 mo, % (95% CI)Overall survival at 18 mo, % (95% CI)Overall survival at 24 mo, % (95% CI)
NABTT historical RT + non-TMZ drug21712 (10.3-12.7)78 (72-83)49 (42-56)22 (16-28)8 (5-13)
EORTC RT + TMZ28714.6 (13.2-16.8)86 (82-90)*61 (55-67)39 (34-45)27 (21-32)§
NABTT RT + TMZ4916.2 (12.9-18.9)88 (75-95)65 (50-78)41 (27-56)20 (10-34)
NABTT RT + TMZ + new agent24419.6 (17.8-21.2)94 (91-97)*81 (75-86)55 (48-61)37 (29-46)§,
  • *P = 0.003.

  • P = 0.0001

  • P = 0.0003.

  • §P = 0.02.

  • As only two trials of the three NABTT trials have mature 24-mo survival data, so this point contains 143 patients.